Generate Biomedicines' IPO
Listed Feb 27, 2026 at $16 on Nasdaq as GENB. Today 40% below its $16 offer price; its first day closed -20.9%.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
What does Generate Biomedicines do?
| Fact | Generate Biomedicines |
|---|---|
| What it does | “We are a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development.” |
| Founded | 2018 |
| Headquarters | Somerville, Massachusetts |
| Employees | 312 full-time, as of December 31, 2025 |
| Website | generatebiomedicines.com |
What is the offering?
Each figure names the filing it is from and that filing's date.
| Fact | Generate Biomedicines |
|---|---|
| Shares offered | 25,000,000 |
| Offer price | $16 a share |
| Raised at that price | $400 million |
| Underwriters' discount | $26 million |
| Underwriters' option | 3,750,000 more shares |
| Underwriters | Goldman Sachs, Morgan Stanley, Piper Sandler, Guggenheim Securities, and Cantor |
| Exchange | Nasdaq Global Select Market, as GENB |
What the filing says about its money
| Fact | Generate Biomedicines |
|---|---|
| Collaboration revenue | $31.9 million, year to December 31, 2025 |
| Net loss | $223 million, year to December 31, 2025 |
| Cash | $222 million, as of December 31, 2025 |
| Last preferred stock | Series C preferred |
What risks does Generate Biomedicines name first?
- “We are a clinical-stage biotechnology company with a limited operating history and no products approved by regulators for commercial sale, which may make it difficult to evaluate our current and future business prospects.”
- “Even if this offering is completed, we will require substantial additional capital to finance our operations in the future.”
- “Our approach to the engineering and development of our programs is unproven, and we may not be successful in our efforts to identify and develop any programs and product candidates of commercial value by leveraging our Generate Platform.”
Dates so far
| What | Day |
|---|---|
| Registration filed | Feb 4, 2026 |
| Exchange registration filed | Feb 24, 2026 |
| Declared effective by the SEC | Feb 26, 2026 |
| Priced | Feb 26, 2026 |
| First trade | Feb 27, 2026 |
| Lock-up ends | Aug 25, 2026 |
How did its first days trade?
From its daily bars, each close against its $16 offer price.
| Day | Open | Close | From the offer |
|---|---|---|---|
| Feb 27 | $15 | $12.65 | -20.9% |
| Mar 2 | $12.01 | $12.17 | -23.9% |
| Mar 3 | $12.36 | $11.93 | -25.4% |
| Mar 4 | $12.40 | $11.58 | -27.6% |
| Mar 5 | $11.34 | $12.45 | -22.2% |
What is Generate Biomedicines' Quality Score?
The other IPOs expected
| Company | Price |
|---|---|
| Tracx Logis | $18 to $22 |
| $11 to $13 | |
| AM PM | $4 to $5 |
| $5 to $6 | |
| Jingrui Wang Pu | $6 |
| $4 to $5 |
Generate Biomedicines IPO questions
When is Generate Biomedicines' IPO?
Listed Feb 27, 2026 at $16 on Nasdaq as GENB.
What is Generate Biomedicines' IPO price?
Generate Biomedicines' IPO priced at $16 a share, per its final prospectus of Feb 27, 2026.
How many shares is Generate Biomedicines selling?
25,000,000 shares, and the underwriters may buy 3,750,000 more, per its final prospectus (424B4).
Who are the underwriters?
Goldman Sachs, Morgan Stanley, Piper Sandler, Guggenheim Securities, and Cantor, as the prospectus's cover names them.
When does the lock-up end?
Generate Biomedicines' IPO lock-up ends Aug 25, 2026. Its final prospectus says: “180 days after the date of this prospectus.”
Does Breakaway rate Generate Biomedicines?
Generate Biomedicines has a Quality Score of -1 today. The score counts the 14 chart checks and the company's filings; a check that needs more history than a new stock has waits for it.
Can Breakaway say where Generate Biomedicines' price will go?
No. Breakaway does not say where a price will go. Every figure here is from the company's SEC filings, linked on each line.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.